Literature DB >> 1082084

Myasthenia gravis unmasked by antiarrhythmic agents.

P Kornfeld, S H Horowitz, G Genkins, A E Papatestas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1082084

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN： 0027-2507


× No keyword cloud information.
  7 in total

Review 1.  Drug interactions with neuromuscular blockers.

Authors:  S Feldman; L Karalliedde
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

2.  Does physostigmine reverse quinidine delirium?

Authors:  W K Summers; R E Allen; F N Pitts
Journal:  West J Med       Date:  1981-11

Review 3.  New treatment approaches to myasthenia gravis.

Authors:  C W Havard; V Fonseca
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 4.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 5.  Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Authors:  S Christopher Jones; Alfred Sorbello; Robert M Boucher
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

Review 6.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 7.  Pathophysiological basis in the management of myasthenia gravis: a mini review.

Authors:  Aiswarya Binu; Sarath S Kumar; Uma Devi Padma; Krishnadas Madhu
Journal:  Inflammopharmacology       Date:  2022-01-21       Impact factor: 4.473
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.